Viking Therapeutics (VKTX) Stock
Clinical stage biotech focused on obesity and metabolic disorders. Here's the price, business snapshot, and what's worth knowing about Viking Therapeutics in July 2026.
Viking Therapeutics, Inc. (VKTX) is a clinical‑stage biopharmaceutical company focused on developing treatments for metabolic and endocrine disorders. With a market capitalisation of about $3.7 billion, Viking advances a pipeline of investigational candidates aimed at conditions such as metabolic liver disease, obesity and related cardiometabolic disorders. Investors should note the company’s profile is typical of small-cap biotech: progress and valuation depend heavily on clinical trial results, regulatory decisions and partnerships or licensing activity. Financial outcomes can be volatile as programmes move through clinical phases and require funding; Viking may raise capital or enter collaborations to support development. Key considerations include trial timelines, data readouts, the competitive landscape in metabolic disease, and management’s capital allocation. This summary is educational only and not personalised investment advice; biotech investments carry substantial risk and potential for significant price fluctuation.
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Viking Therapeutics' stock with a target price of $101.37, indicating strong growth potential.
Financial Health
Viking Therapeutics is showing strong cash flow and a solid book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABCELLERA BIOLOGICS INC
AbCellera Biologics Inc is a biotechnology company that provides technology to discover and develop novel fully human monoclonal antibodies.
Baskets Featuring VKTX
Oral Obesity Treatments: Investment Theme Explained
Novo Nordisk has launched the first oral GLP-1 weight loss medication, Wegovy, representing a major evolution in the obesity treatment landscape. This shift from injections to pills creates an investment opportunity in pharmaceutical innovators and the digital health companies enabling broad access.
Published: 6 January 2026
Explore BasketBiotech Buyout Wave Targets Obesity Market 2025
Pfizer's bid for obesity drug maker Metsera has turned into a legal battle after a counteroffer from Novo Nordisk, highlighting the fierce competition in the weight-loss market. This intense M&A activity signals that other biotech companies with promising obesity treatments could become the next valuable acquisition targets.
Published: 1 November 2025
Explore BasketCardio-Metabolic Drugs: Beyond Weight Loss Benefits
Following new data showing Novo Nordisk's Wegovy has superior cardiovascular benefits over a key rival, the competitive landscape for weight-loss drugs has intensified. This theme focuses on the pharmaceutical giants battling for dominance and the innovative biotechs whose research in related metabolic and cardiovascular fields is now more valuable than ever.
Published: 1 September 2025
Explore BasketWhy You’ll Want to Watch This Stock
Pipeline Catalysts Ahead
Clinical trial readouts and regulatory milestones can materially move the stock, offering potential opportunities but also significant downside if results disappoint.
Growth & Volatility
Market capitalisation reflects expectations for future success; small‑cap biotech shares can swing widely, so consider risk tolerance and investment horizon.
Competitive Landscape
Metabolic and liver disease are active areas with competing approaches; regulatory and commercial dynamics will influence long‑term prospects.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
